UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 For the Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis(
July 17, 2014 at 16:03 PM EDT
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of ...
